Loading...
Pirfenidone inhibits myofibroblast differentiation and lung fibrosis development during insufficient mitophagy
BACKGROUND: Pirfenidone (PFD) is an anti-fibrotic agent used to treat idiopathic pulmonary fibrosis (IPF), but its precise mechanism of action remains elusive. Accumulation of profibrotic myofibroblasts is a crucial process for fibrotic remodeling in IPF. Recent findings show participation of autoph...
Na minha lista:
| Udgivet i: | Respir Res |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5457546/ https://ncbi.nlm.nih.gov/pubmed/28577568 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-017-0600-3 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|